{"id":"axalimogene-filolisbac","safety":{"commonSideEffects":[{"rate":"20%","effect":"Fatigue"},{"rate":"15%","effect":"Nausea"},{"rate":"10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Axalimogene filolisbac is a live, attenuated Listeria monocytogenes-based immunotherapy that selectively targets and kills tumor cells by inducing a strong immune response.","oneSentence":"Lysosomal targeting of tumor cells via Listeria monocytogenes","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:11.388Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cervical cancer"}]},"trialDetails":[{"nctId":"NCT02164461","phase":"PHASE1","title":"Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer","status":"COMPLETED","sponsor":"Advaxis, Inc.","startDate":"2015-03-04","conditions":"Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer, Cervical Adenocarcinoma","enrollment":12},{"nctId":"NCT02399813","phase":"PHASE2","title":"A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal","status":"COMPLETED","sponsor":"Advaxis, Inc.","startDate":"2016-06-02","conditions":"Anal Cancer, Rectal Cancer","enrollment":36},{"nctId":"NCT02002182","phase":"PHASE2","title":"ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer","status":"COMPLETED","sponsor":"Andrew Sikora","startDate":"2013-12","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ADXS11-001"],"phase":"phase_2","status":"active","brandName":"Axalimogene filolisbac","genericName":"Axalimogene filolisbac","companyName":"Advaxis, Inc.","companyId":"advaxis-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lysosomal targeting of tumor cells via Listeria monocytogenes Used for Cervical cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}